Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMI:TSE International Medical Innovations Inc. -- Ignore unavailable to you. Want to Upgrade?

To: gg cox who wrote (29)	9/10/2003 10:35:07 AM
From: gg cox	Read Replies (1) \| Respond to of 66

globeinvestor.com Investors flock to IMI after deal struck Skin cholesterol test to be used in study By LEONARD ZEHR 00:00 EDT Friday, August 29, 2003 Investors jumped into IMI International Medical Innovations Inc. yesterday after the medical devices maker signed a collaborative research pact to supply its flagship skin cholesterol test for a major late-stage clinical study of an anti-inflammatory pill to target hardening of the arteries. The stock closed up 14 cents at $3.25 on the Toronto Stock Exchange as volume climbed to 75,200 shares, almost four times the daily average. Under the accord, Toronto-based IMI will supply its Cholesterol 1,2,3 test to AtheroGenics Inc., which is undertaking a $40-million (U.S.) Phase III trial to test 4,000 patients at 180 cardiac clinics in North America, Britain and South Africa with its AGI-1067 drug. In return, it will have full access to the trial data. "The use of Cholesterol 1,2,3 in this large clinical trial will serve to raise the product's visibility with opinion leaders at some of the leading cardiac centres throughout the world," said Loewen Ondaatje McCutcheon Ltd. analyst Mark Knapp. He rates the stock a "speculative buy," with a 12-month target price of $6 (Canadian). Another analyst, who asked not to be identified, said the agreement with AtheroGenics will not affect IMI's bottom line and valuation. "But it will give the skin test wider recognition with cardiologists and could validate the relationship between skin cholesterol readings and cardiac events." IMI president and chief executive officer Dr. Brent Norton said the study will provide some of the most important data ever collected on skin cholesterol testing. "Joining the . . . study is consistent with our strategy of leveraging large trials led by other corporate and government organizations," he added. Rob Scott, chief medical officer of Alpharetta, Ga.-based AtheroGenics, said skin cholesterol appears to correlate with cholesterol levels in other tissue, such as the artery wall. "This in turn may correlate with the progression of coronary artery disease and associated clinical events such as heart attack or death, as well as the effect of AGI-1067 on atherosclerosis," he said. IMI's 1,2,3 skin test has already been cleared for sale, with an expected launch through Johnson & Johnson's McNeil Consumer Healthcare unit in the fourth quarter, Paradigm Capital Inc. analyst David Ng said in a recent report. Various delays in the launch have "caused uncertainty and has resulted in a depressed stock price over the last 12 months," he said. Still, he rates the stock a "buy," with a 12-month target price of $8. © The Globe and Mail

To: gg cox who wrote (29)	9/16/2003 12:03:23 AM
From: gg cox	Read Replies (2) \| Respond to of 66

Overview 2003, 2004: cash on hand $8.9 Million Aug 2003 (2-3 years at current burn) 13 new clinical trials commenced in 2003 30 total trials in the field of which we pay only 20% Currently 4 products are in the pipeline. They should hit the market at the rate of 1 pipe per year in this order: CH123/ D'tect ColorectAlert LungAlert BreastAlert CH123 is 3 products: Tape Test, Wallet Test, Lab test attacking 6 markets: Physicians offices, Insurance testing, Occupational Health, Home, Co- Promotion, Pharmacies Completed Milestones by timeline: CH123: Pivotal trials commence November 1997 ColorectAlert: IMI licences test for detection of early stage colorectal cancer May 1998 ColorectAlert: IMI files patent application for colorectal cancer detection test January 1999 LungAlert: IMI files patent application for lung cancer detection test January 1999 ColorectAlert: Announced May 2000, clinically more accurate than fecal occult blood testing (FOBT) CH123: January 29, 2001, Canadian marketing clearance LungAlert: May 2001 American Thoracic Society, 1st and only early stage test CH123: June 11, 2001 FDA submission CH123: July 10, 2001 DCL agrees to make CH123 CH123: September 5, 2001 SG Cowen Securities hired CH123: October 29, 2001 resubmission to FDA, shares tank to $3.00 CH123: February 25, 2002 Multi-Ethnic Study of Atherosclerosis (MESA 6500 souls) CH123: April 8, 2002 Sprecher breakthrough at American Heart Association ColorectAlert: April 15, 2002 ColorectAlert beats FOBT financially CH123: May 10, 2002 McNeil CDN partnership announced CH123: June 2002 American Journal of Cardiology paper, Mancini CH123: June 24, 2002 FDA approval CH123: Sept. 2002 European approval CH123 @ home: Oct Q4 2002 Unveiling of 2 new modified home tests CH123: Oct. 28th 2002 McNeil demos 123 at the Canadian Cardiovascular Congress, Edmonton CH123: December 2002 signs agreement with McNeil to expand US marketing to the insurance industry, no FDA required CH123: Feb 27th 2003 Revenue commences with Milestone Payment $100,000 CH123: June 2003 Australian Approval CH123: June 2003 Found to be reliable and harmless in testing Pediatric cholesterol D-TECT: Feb 27th 2003 new Coronary Heart Disease Predictor announced SEC Approval: March 12th 2003 clears IMI for a US listing American Association for Cancer Research to publish Cancer Suite Papers, Toronto meeting cancelled due to SARS Apr. 2, 2003 ColorectAlert Trial results announced Apr. 5, 2003 detected 54% early stage colon cancer, 85% accurate clearing non cancer patients LungAlert: Q2 2003, Japanese trial with major Japanese Partner commences LungAlert: Trial results announced Apr. 5, 2003 detected 57% early stage lung cancer, only 10% false positives BreastAlert Apr 03 preliminary trial results encouraging John Hopkins Aug 03; Skin cholesterol is more strongly associated with Arteiosclerosis than blood tests AtheroGenics Aug 03. a $40-million Phase III trial to test 4,000 heart patients uses CH123 Amex Sept 19 2003: IMI begins trading on the American Stock Exchange symbol IME Milestones yet to come with approximate timing: CH123: ISO certification Q4 2003 CH123: Japanese Approval Process completing Q4 2003 CH123: Revenue stream commences Q4 2003 CH123: Announcement of World Wide and or US Partners 2004 D-TECT: McNeil to launch in multiple markets 2004 ColorectAlert: Canadian Approval 2004 ColorectAlert: FDA trials commence 2004 LungAlert: Canadian Approval 2004 LungAlert: FDA trials commence 2004 BreastAlert: expanded trials 2003 -2004 US and EU Development Partners on the Cancer Suite 2004 stockhouse.com